Book Navigation
x

We are sorry, but signing in with LinkedIn is not possible at this time.

 

Sophie Blanchard

Member of the GIN Board of Trustees 2016 -2019; 2020 - 2023

 

Sophie Blanchard-Musset, Ph.D.

Her training and background are in biomedical research (infectious diseases, virology, bacteriology, immunology, biotechnology). After her Ph. D. in medical biology (1999, Bordeaux University), she’s been in charge of several research projects at the French National Institute of Health and Medical Research and bio engineering schools.  

In 2005, she joined The French National Authority for Health (HAS). From 2005 to 2011 she worked for its health technology assessment (HTA) department and performed several devices and procedures assessments. During this period, always interested in the medical innovation field, she’s been involved in the International Information Network on New and Emerging Health Technologies (EuroScan) whose aim is to share information and development of methods for the early identification and assessment of new health-related technologies. 

In 2012, she joined the HAS office of guideline development. She has managed more than 17 clinical practice guidelines and rapid guidelines in different fields (diabetology, enhanced recovery after surgery, gynecology, cancerology, mental health,). One part of her job is also to develop new tools and methods to improve the development and dissemination of the evidence based guidelines: updating guidelines, adaptation and developing guidelines in an accelerated way. In this context, she is as a co funder of the Accelerated Guideline Development Working Group to provide a method for helping the GIN members to develop guidelines in an accelerated time frame without losing in scientific quality. 

During the coronavirus disease 2019 (COVID-19) pandemic, she performed with her team a specific method to provide urgently requested guidelines (“réponses rapides -covid-19”) to support decision making by ministry of health and medical teams in different fields: diagnostic tests (rt-PCR, serologic tests), chronic disease management during lockdown, pregnancy management, rehabilitation management in the intensive care unit, health mental, teleconsultation... This unprecedented pace of development of guidelines for Covid 19 reiterated her determination to participate in the efforts of the international community to doing better in the care delivery.

Vision for GIN  2020-2023

The pandemic Covid 19 has exacerbated the many challenges guidelines developers already face and has highlighted several strengths and weaknesses in all the health care systems. The GIN network has reached a maturity and legitimacy in the field of evidence-based guidelines and we all experienced significant benefits from GIN´s activities in the recent international efforts against COVID-19. 

Four foundational principles, the FAIR principles, were recently defined to maximize the added value gained by digital dataFindability, Accessibility, Interoperability, and Reusability. I do think that these principles apply to our network and so, the “FAIR “GIN priorities should be for the next few years:

  • To intensify and improve exchanges and collaborations between GIN members, working groups and communities by using interactive and innovative technologies. 
  • To continue efforts to increase GIN reputation as major player in the global healthcare quality field. Some actions can be directed to disseminate GIN outputs (methods, tools) and increase their impacts, to encourage and support publications from working Groups and communities, to maintain ongoing efforts to improve the website and G-I-N Library or rolling out guideline credentialing for members. 
  • To engage exchanges with other organisations in the health field (evidence synthesis, health technology assessment, and evidence based health care, implementation and knowledge management). In particular, the GIN network could develop partnerships with other networks (ISQua, HTAi, WHO, European funds, EuroScan, EuneHTA, etc…). 
  • Moreover, for the next period, our network should stand for anticipating and accompanying the substantial digital changes and the great challenges the guidelines developers are faced to the next years: Real World Data, Big-Data, personalised medicine, innovative digital – health products, etc. 

 

 

 

Page last updated: Oct 01, 2020
Back to top